clinical trial · NCT07118215
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
Karuna Therapeutics, Inc., a Bristol Myers Squibb company·phase1·recruiting·n = 60
Healthy VolunteersKarXTMidazolamFexofenadineDigoxin
brief summary
The purpose of this study is to evaluate the effects of KarXT administration on the drug levels of midazolam, fexofenadine, and digoxin in healthy adult participants.
started
Sep 29, 2025
primary completion
Jun 25, 2026
completion
Jun 25, 2026
last updated
Jun 11, 2026
official title
A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol